This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.

Inclusion Criteria:

• Confirmed HCC based on histopathological findings from tumor tissues or radiologically findings.
• Must not have received prior systemic therapy for unresectable HCC.
• Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C.
• Child-Pugh Score class A.
• ECOG performance status of 0 or 1 at enrollment.
• At least 1 measurable lesion per RECSIT 1.1 guidelines

Exclusion Criteria:

• Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Grade ≥2 from previous anticancer therapy.
• History of hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy.
• Clinically meaningful ascites.
• Patients with main portal vein thrombosis.
• Active or prior documented GI bleeding.
• Patient currently exhibits symptomatic or uncontrolled hypertension.
• Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D virus (HDV)
• Uncontrolled intercurrent illness

Qualified researchers can request access to anonymized individual patient- level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

Plan Description: All request will be evaluated as per the Az disclosure commitment:

https://astrazenecaarouptrials.pharmacm.com/ST/Submission/Disclosure Yes. indicates that Az are accepting requests for IPD ,but this does not mean are quests will be shared

AstraZeneca will meet or exceed data availability as per the commitment at made to the EFPIA Pharma Data Sharing Principles .For details of our timeline please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool.

Signed Data Sharing Agreement(non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to a air access. For additional details. please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.